MCID: WDH001
MIFTS: 34

Wdha Syndrome

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Wdha Syndrome

MalaCards integrated aliases for Wdha Syndrome:

Name: Wdha Syndrome 54 56
Pancreatic Cholera 54 74
Watery Diarrhea, Hypokalemia, and Achlorhydria Syndrome 54
Verner-Morrison Syndrome 54
Watery Diarrhea Syndrome 54
Vipoma Syndrome 54

Classifications:



External Ids:

UMLS 74 C0086768

Summaries for Wdha Syndrome

MalaCards based summary : Wdha Syndrome, also known as pancreatic cholera, is related to vipoma and pancreatic cholera. An important gene associated with Wdha Syndrome is VIP (Vasoactive Intestinal Peptide), and among its related pathways/superpathways are Neuroscience and G alpha (s) signalling events. The drugs Bevacizumab and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, bone and small intestine.

Wikipedia : 77 A VIPoma or vipoma (/vɪˈpoʊmə/) is a rare endocrine tumor that overproduces vasoactive intestinal... more...

Related Diseases for Wdha Syndrome

Diseases related to Wdha Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 vipoma 32.6 SST VIP
2 pancreatic cholera 31.9 CALCA SST VIP
3 glucagonoma 29.6 SST VIP
4 pheochromocytoma 29.6 CALCA SST VIP
5 islet cell tumor 29.3 CALCA SST VIP
6 multiple endocrine neoplasia, type i 29.3 SST VIP
7 cholera 10.6
8 large cell carcinoma 10.4
9 diarrhea 10.2
10 hypokalemia 10.2
11 ganglioneuroma 10.0
12 leprosy 2 10.0 CALCA VIP
13 vasomotor rhinitis 10.0 CALCA VIP
14 neurofibromatosis, type i 10.0
15 neurofibromatosis, type iv, of riccardi 10.0
16 insulinoma 10.0
17 ganglioneuroblastoma 10.0
18 adenoma 10.0
19 cluster headache 10.0 CALCA VIP
20 diffuse pulmonary fibrosis 10.0 CALCA VIP
21 small cell carcinoma 10.0
22 pancreatic somatostatinoma 9.9 CALCA SST
23 duodenal somatostatinoma 9.9 CALCA SST
24 prolactin producing pituitary tumor 9.9 CALCA SST
25 carcinoid syndrome 9.9 CALCA SST
26 secretory diarrhea 9.8
27 multiple endocrine neoplasia 9.8
28 malignant pheochromocytoma 9.8 CALCA SST
29 postgastrectomy syndrome 9.8 SST VIP
30 endocrine organ benign neoplasm 9.8 CALCA SST
31 fibrous dysplasia 9.8 CALCA SST
32 thyroid gland disease 9.8 CALCA SST
33 binswanger's disease 9.8 SST VIP
34 cryptosporidiosis 9.8 SST VIP
35 migraine with or without aura 1 9.8 CALCA VIP
36 gastrinoma 9.8 SST VIP
37 thyroid carcinoma, familial medullary 9.7 CALCA SST
38 hyperprolactinemia 9.7 SST VIP
39 neuroendocrine tumor 9.7 CALCA SST
40 pertussis 9.7 SST VIP
41 thyroid cancer, nonmedullary, 2 9.6 CALCA SST
42 somatostatinoma 9.5 CALCA SST VIP
43 constipation 9.5 CALCA SST VIP
44 endocrine gland cancer 9.5 CALCA SST VIP
45 small cell cancer of the lung 9.5 CALCA SST

Graphical network of the top 20 diseases related to Wdha Syndrome:



Diseases related to Wdha Syndrome

Symptoms & Phenotypes for Wdha Syndrome

Drugs & Therapeutics for Wdha Syndrome

Drugs for Wdha Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
2
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
3
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 6857599 5310940 9887054 43805
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1 59763-91-6
9 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1
10 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
11 Antimetabolites Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3
13 Vitamin B9 Phase 2, Phase 3
14 Folate Phase 2, Phase 3
15 Immunologic Factors Phase 2, Phase 3,Phase 1
16 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
17 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
18 Liver Extracts Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 3
20 Anesthetics, Intravenous Phase 3
21 Cola Phase 3,Phase 2,Phase 1
22 Central Nervous System Depressants Phase 3
23 Narcotics Phase 3
24 Anesthetics, General Phase 3
25 Adjuvants, Anesthesia Phase 3
26 Analgesics, Opioid Phase 3
27 Analgesics Phase 3
28 Anesthetics Phase 3
29
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
32
Pancrelipase Approved, Investigational Phase 2 53608-75-6
33
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
34
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
35
Melphalan Approved Phase 2 148-82-3 460612 4053
36
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
37
Calcium Approved, Nutraceutical Phase 2,Phase 1 7440-70-2 271
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
39
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
40 Protein Kinase Inhibitors Phase 2
41 Hormones Phase 2,Phase 1
42 Micronutrients Phase 2
43 Antidotes Phase 2,Phase 1
44 Calcium, Dietary Phase 2,Phase 1
45 pancreatin Phase 2
46 Vitamins Phase 2
47 Trace Elements Phase 2
48 Topoisomerase Inhibitors Phase 2
49 Bone Density Conservation Agents Phase 2
50 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
4 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
5 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
6 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
7 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
8 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
9 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
10 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
11 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
12 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
13 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
14 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
15 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
16 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376

Search NIH Clinical Center for Wdha Syndrome

Genetic Tests for Wdha Syndrome

Anatomical Context for Wdha Syndrome

MalaCards organs/tissues related to Wdha Syndrome:

42
Pancreas, Bone, Small Intestine, Pancreatic Islet

Publications for Wdha Syndrome

Articles related to Wdha Syndrome:

(show top 50) (show all 57)
# Title Authors Year
1
Hypokalemic rhabdomyolysis due to watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome caused by vipoma. ( 19488018 )
2009
2
VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. ( 19184565 )
2009
3
A Pancreatic Polypeptide-Producing Pancreatic Tumor Causing WDHA Syndrome. ( 21490894 )
2008
4
Hypokalemic rhabdomyolysis due to WDHA syndrome caused by VIP-producing composite pheochromocytoma: a case in neurofibromatosis type 1. ( 16027147 )
2005
5
A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. ( 14716055 )
2003
6
Surgical treatment of pancreatic cholera: a case report. ( 8769928 )
1996
7
Increased tear secretion in pancreatic cholera: a newly recognized symptom in an experiment of nature. ( 2845780 )
1988
8
Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology. ( 2828145 )
1988
9
Treatment of pancreatic cholera. ( 2827972 )
1988
10
Multiple endocrine neoplasia, type 1, with pancreatic cholera. ( 2886044 )
1987
11
A multihormonal tumor of the pancreas producing neurotensin associated with the WDHA syndrome. Histology, histochemistry and origin. ( 2856535 )
1986
12
Secretin, cholecystokinin, and vasoactive intestinal polypeptide in pancreatic cholera. ( 3019205 )
1986
13
Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. ( 2856888 )
1985
14
Pancreatic endocrine tumours associated with WDHA syndrome. An immunohistochemical and electron microscopic study. ( 2579503 )
1985
15
Successful treatment of therapy-resistant pancreatic cholera with human leucocyte interferon. ( 2857998 )
1985
16
Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. ( 2862821 )
1985
17
Pancreatic cholera. ( 6322070 )
1984
18
The WDHA syndrome: clinical and laboratory data on 28 Japanese cases. ( 6473165 )
1984
19
The exocrine pancreas of patients with WDHA syndrome. A light and electron microscopical study. ( 6471149 )
1984
20
VIP and the pancreatic cholera syndrome. ( 6325912 )
1984
21
Pancreatic cholera: is the diarrhea due to VIP? ( 6316137 )
1983
22
WDHA syndrome caused by VIP-producing ganglioneuroblastoma. ( 6288909 )
1982
23
Streptozotocin treatment in pancreatic cholera (Verner-Morrison) syndrome. ( 6292031 )
1982
24
Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. ( 6122550 )
1982
25
Beneficial effect of oral lithium carbonate in the treatment of pancreatic cholera syndrome. ( 6246427 )
1980
26
Clinical and hormonal aspects of the watery diarrhea-hypokalemia-achlorhydria (WDHA) syndrome due to vasoactive intestinal polypeptide (VIP)-producing tumor. ( 7014208 )
1980
27
Effects fo streptozotocin in the WDHA syndrome not amenable to radical surgery. ( 6253557 )
1980
28
Lithium carbonate in pancreatic cholera. ( 7421906 )
1980
29
Angiographic diagnosis of a pancreatic islet tumor in a patient with the WDHA syndrome. ( 6252088 )
1980
30
Effects of streptozotocin in the WDHA syndrome not amenable to radical surgery. ( 6152975 )
1980
31
Trifluoperazine reversal of secretory diarrhea in pancreatic cholera. ( 6250437 )
1980
32
The pancreatic cholera syndrome. ( 6244130 )
1980
33
VIP and the WDHA syndrome. ( 437409 )
1979
34
A pancreatic-polypeptide-producing tumour associated with the WDHA syndrome. ( 151327 )
1978
35
Angiographic demonstration of a vasoactive intestinal polypeptide-secreting pheochromocytoma in a patient with WDHA syndrome. ( 413408 )
1978
36
Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment. ( 208414 )
1978
37
WDHA syndrome caused by pheochromocytoma: report of a case. ( 657943 )
1978
38
Indomethacin-responsive pancreatic cholera. ( 197410 )
1977
39
Intractable diarrhea. Intestinal perfusion studies and plasma VIP concentrations in patients with pancreatic cholera syndrome and surreptitious ingestion of laxatives and diuretics. ( 857657 )
1977
40
Angiographic demonstration of a pancreatic "vipoma" in the WDHA syndrome. ( 187070 )
1976
41
Radiologic and pathologic characteristics of the WDHA syndrome. ( 183523 )
1976
42
Watery diarrhoea (WDHA) syndrome associated with carcinoma of the lung. ( 193482 )
1976
43
The VIPoma: further confirmation of VIP as the hormonal agent in the WDHA syndrome. ( 998869 )
1976
44
Pancreatic cholera. ( 173092 )
1975
45
Letter: Treatment of "pancreatic cholera". ( 166314 )
1975
46
Pancreatic cholera. Sudies on tumoral secretions and pathophysiology of diarrhea. ( 1097288 )
1975
47
Editorial: Streptozotocin for pancreatic cholera.'. ( 49526 )
1975
48
Islet cell carcinoma, pancreatic cholera, and vasoactive intestinal peptide. ( 173221 )
1975
49
Letter: Pancreatic cholera and vip. ( 1160944 )
1975
50
Pancreatic cholera (W.D.H.A. syndrome). Histochemical and ultrastructural studies. ( 170729 )
1975

Variations for Wdha Syndrome

Expression for Wdha Syndrome

Search GEO for disease gene expression data for Wdha Syndrome.

Pathways for Wdha Syndrome

Pathways related to Wdha Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.49 CALCA VIP
2 10.79 CALCA VIP

GO Terms for Wdha Syndrome

Cellular components related to Wdha Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.33 CALCA SST VIP
2 neuron projection GO:0043005 8.96 CALCA VIP
3 neuronal cell body GO:0043025 8.62 CALCA SST

Biological processes related to Wdha Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.5 CALCA SST VIP
2 cell-cell signaling GO:0007267 9.37 CALCA SST
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.26 CALCA VIP
4 response to heat GO:0009408 9.16 CALCA SST
5 regulation of signaling receptor activity GO:0010469 9.13 CALCA SST VIP
6 positive regulation of blood vessel diameter GO:0097755 8.62 CALCA VIP

Molecular functions related to Wdha Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA SST VIP

Sources for Wdha Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....